Wall Street ended the fourth quarter on a solid note despite the turbulence in the final month. The Nasdaq Composite and the S&P 500 rose for the fifth consecutive quarter for the first time since 2021,...
Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.
Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...
After reaching a record high on optimism surrounding corporate growth under President-elect Donald Trump, all three major bourses lost momentum as sticky inflation and the Fed’s hawkish comments weighed...
Wall Street has shown a remarkable rally with the three major indices on track to wrap up the first nine months of 2024 near record highs. The artificial intelligence (AI) craze and rate-cut optimism have...
NetworkNewsWire Editorial Coverage : Global destigmatization, changing regulations and an upswing in research are speaking loudly to the opportunity for psychedelics to provide tangible improvements in...
/PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics...
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
On Sept. 16, the AdvisorShares Psychedelics ETF (NYSE Arca: PSIL) began trading. Its monumental because ...
The AdvisorShares® Psychedelics ETF has commenced trading under ticker NYSE: PSIL